Biotech and Nvidia: Investments and Regulatory Flexibility

This chapter discusses the intersection between biotech and Nvidia, highlighting Nvidia's investments in biotech startups and their plans for future investments. It also explores the FDA's review of gene therapies, specifically discussing Sarepta Therapeutics and the potential approval of their gene therapy. The chapter further delves into the implications of regulatory flexibility and its impact on the stock market, before shifting to the hosts' personal experiences and events of the week.